Markets
US Trade down Trade bargains discounters
(CSA Archive/Getty Images)

The trade-down trade is a market theme worth watching

Annoyingly high costs of living are driving bargain hunting and big gains for discounters.

8/29/25 11:31AM

Earnings season came to its usual, consumer-oriented conclusion over the last couple weeks, with a flurry of quarterly reports from retailers peppering the tape.

The market was clearly taken aback by some superstrong numbers from a few unsexy off-price retailers. Kohl’s mooned 24% Wednesday after posting its numbers. Burlington Stores rose a more muted 5% Thursday for the same reason, as did Five Below, which gained about 4%. Others like Dollar General and TJX Maxx parent TJX Cos. also did much better than expected, even if the stock reaction wasn’t so dramatic.

The upside wasn’t uniform — Ross Stores posted slightly disappointing sales last week, for instance — but in the aggregate, the news seemed to reinforce the message of an interesting chart published in a note by Bank of America analysts.

Trade Down Stock Market Theme
(Bank of America Global Research)

This trend line charts the change in mentions of “trading down” — that is, consumers shopping for lower-priced options rather than paying premium prices — on conference calls hosted by large US companies over the last 20 years.

Mentions of such behavior spiked during great financial crisis of 2008-09, and then again a decade or so later during the post-Covid inflation, as consumers saw their buying power weaken either because of job losses during the recession or because their pay didn’t keep up with price increases after the pandemic.

After a brief respite, this chart says (and the recent numbers from discounters confirm) that trading down is back.

This makes sense, as inflation remains stubbornly high. Actually it’s a bit worse than that, as inflation is actually accelerating.

The Fed’s preferred measure of underlying inflationary pressures, core PCE, hit an annual rate of nearly 3% last month, up from 2.6% back in April, according to data released Friday. It was the third straight monthly increase.

At the same time, the job market, while more or less stable, seems to be softening a bit on the margin, with the number of those receiving continued unemployment benefits rising and net employment growth decelerating, both of which make it harder to switch jobs or push for higher pay.

That might sound like an uncomfortable world for workers.

But it’s a solid backdrop for stocks of bargain retailers. Such stocks might be a decent place for risk-averse investors — if such a breed still exists — to hunt for relatively safe trades that could perform well in the high-inflation, soft-growth economy we might be looking at for a while.

More Markets

See all Markets
markets

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Shares of Robinhood Markets, AppLovin, and Emcor are all rallying in post-market trading on Friday upon news that they’re being added to the S&P 500.

Shares of the brokerage popped 7.2%, the adtech company rose 7.8%, and the construction company was up a more modest 2.7% in the minutes following the announcement.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Strategy, another stock rumored to be in the running for inclusion in the benchmark US stock index that has been passed over, sank 2.5% in postmarket trading.

markets

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

markets

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

It’s been a shortened week, but still a rough one for Lucid. Investor blowback to the luxury EV maker’s 1-for-10 reverse stock split has sent shares to all time lows this week.

After six straight days of closing lower, Wall Street appears to have decided enough is enough and is loading up on Lucid shares on Friday, sending them up 13% in recent trading. As of 2:10pm eastern, Lucid trading volumes were at more than 240% of their 30 day average.

Some of the move could be attributed to traders reading headlines that don’t take into consideration Lucid’s reverse split. Cantor Fitzgerald on Friday slapped a new price target on Lucid of $20, compared to its previous target of $3. Some news outlets (not us!) presented that as an increase. The problem: With the 1-for-10 reverse split in effect, a comparable price target would have been $30. The new $20 target is actually... a cut.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.